These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37101716)

  • 21. RelB is a potential molecular biomarker for immunotherapy in human pan-cancer.
    Wu J; Yu X; Zhu H; Chen P; Liu T; Yin R; Qiang Y; Xu L
    Front Mol Biosci; 2023; 10():1178446. PubMed ID: 37388242
    [No Abstract]   [Full Text] [Related]  

  • 22. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comprehensive pan-cancer analysis of CDH5 in immunological response.
    Li Y; Wu Q; Lv J; Gu J
    Front Immunol; 2023; 14():1239875. PubMed ID: 37809080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
    Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
    Liu P; Wang X; Pan L; Han B; He Z
    Front Immunol; 2022; 13():901784. PubMed ID: 35720327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pan-Cancer Analysis of OLFML2B Expression and Its Association With Prognosis and Immune Infiltration.
    Hu P; Zhang X; Li Y; Xu L; Qiu H
    Front Genet; 2022; 13():882794. PubMed ID: 35873458
    [No Abstract]   [Full Text] [Related]  

  • 27. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pan-cancer analysis of SYNGR2 with a focus on clinical implications and immune landscape in liver hepatocellular carcinoma.
    Liu C; Qu Z; Zhao H; Wang P; Zhan C; Zhang Y
    BMC Bioinformatics; 2023 May; 24(1):192. PubMed ID: 37170221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
    Shen C; Fu C; Suo Y; Li K; Zhang Z; Yang S; Zhang Y; Lin Y; Li Z; Wu Z; Huang S; Chen H; Fan Z; Hu H
    Heliyon; 2023 Jun; 9(6):e16897. PubMed ID: 37346342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pan-Cancer Integrated Analysis of HSF2 Expression, Prognostic Value and Potential Implications for Cancer Immunity.
    Chen F; Fan Y; Liu X; Zhang J; Shang Y; Zhang B; Liu B; Hou J; Cao P; Tan K
    Front Mol Biosci; 2021; 8():789703. PubMed ID: 35087869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The importance of BUD13 in the prognosis of hepatocellular carcinoma revealed by pan-cancer analysis.
    He H; Qiu Z
    Cell Mol Biol (Noisy-le-grand); 2023 Jun; 69(6):41-48. PubMed ID: 37605593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comprehensive pan-cancer analysis on the immunological role and prognostic value of
    Yang Y; Jiang L; Wang S; Chen H; Yi M; Wu Y; Li Z; Fang X
    Transl Cancer Res; 2022 Sep; 11(9):3187-3208. PubMed ID: 36237259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prognostic and immunological analysis of 7B-containing Kelch structural domain (KLHDC7B) in pan-cancer: a potential target for immunotherapy and survival.
    Ding J; Ji X; Liu L; Chen DZ; Luo N; Yu XT; Guo F
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7857-7876. PubMed ID: 37039902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comprehensive pan-cancer analysis identifies a novel glycolysis score and its hub genes as prognostic and immunological biomarkers.
    Zheng D; Long S; Xi M
    Transl Cancer Res; 2023 Oct; 12(10):2852-2874. PubMed ID: 37969385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic pan-cancer analysis identifies transmembrane protein 158 as a potential therapeutic, prognostic and immunological biomarker.
    Li J; Hou H; Sun J; Ding Z; Xu Y; Li G
    Funct Integr Genomics; 2023 Mar; 23(2):105. PubMed ID: 36977915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive Pan-Cancer Analysis Confirmed That ATG5 Promoted the Maintenance of Tumor Metabolism and the Occurrence of Tumor Immune Escape.
    Xu C; Zang Y; Zhao Y; Cui W; Zhang H; Zhu Y; Xu M
    Front Oncol; 2021; 11():652211. PubMed ID: 33842365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of YAP1 in survival prediction, immune modulation, and drug response: A pan-cancer perspective.
    Hu X; Zhang Y; Yu H; Zhao Y; Sun X; Li Q; Wang Y
    Front Immunol; 2022; 13():1012173. PubMed ID: 36479120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pan-cancer analysis of AIM2 inflammasomes with potential implications for immunotherapy in human cancer: A bulk omics research and single cell sequencing validation.
    Qin Y; Pan L; Qin T; Ruan H; Zhang Y; Zhang Y; Li J; Yang J; Li W
    Front Immunol; 2022; 13():998266. PubMed ID: 36248785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pan-Cancer Analyses Confirmed the Ferroptosis-Related Gene
    Lin Y; Dong Y; Liu W; Fan X; Sun Y
    Int J Gen Med; 2022; 15():2501-2513. PubMed ID: 35282646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
    Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
    Front Genet; 2022; 13():993438. PubMed ID: 36685895
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.